IL-15 (Interleukin-15): Complete Research Profile — IL-15Rα Trans-Presentation, NK Cell Homeostasis, CD8+ Memory T Cell Biology, and Cancer Immunotherapy Research Applications (2026)

Introduction

Interleukin-15 (IL-15) occupies a unique position in cytokine biology: it shares its signaling receptor complex with IL-2 yet engages that complex through a fundamentally different delivery mechanism called trans-presentation. Cloned in 1994 by Grabstein and colleagues, IL-15 emerged from screening for factors capable of sustaining T cell proliferation in the absence of IL-2 (Grabstein KH et al., Science 1994, PMID 8171324). Since then, IL-15 has become recognized as the master homeostatic cytokine for natural killer (NK) cells and CD8⁺ memory T cells, with substantial research interest in autoimmunity, infection biology, and cancer immunotherapy.

This article provides a comprehensive research profile of IL-15: its unusual receptor architecture, trans-presentation mechanism, downstream signaling, immunobiology across innate and adaptive compartments, and the landscape of recombinant tools and engineered superagonists used in laboratory investigation.

---

Gene, Protein Structure, and Expression

The human IL15 gene is located on chromosome 4q31, spanning approximately 34 kilobases — unusually large for a cytokine gene, largely due to an exceptionally long 3′ untranslated region containing multiple mRNA instability elements that enforce post-transcriptional regulation. The mature IL-15 protein contains 114 amino acids after processing, folding into the canonical four-α-helix bundle topology shared with IL-2, IL-4, and other short-chain cytokines, with a calculated molecular weight of approximately 14–15 kDa.

A defining structural feature that sets IL-15 apart from all other cytokines is the existence of two distinct signal peptides encoded from alternative translation initiation codons:

• •Long Signal Peptide (LSP, 48 aa): Targets IL-15 to the endoplasmic reticulum (ER), where it undergoes N-linked glycosylation and is routed toward the secretory pathway. However, even with LSP, IL-15 is inefficiently secreted; ER retention and proteasomal degradation reduce net secretion dramatically.
• •Short Signal Peptide (SSP, 21 aa): Lacks canonical ER-targeting capacity, producing a cytoplasmic or nuclear form whose biological function remains under active investigation.

Critically, most cellular IL-15 produced in vivo is never secreted freely — it instead undergoes intracellular association with IL-15Rα before being co-transported to the cell surface as a preformed complex. This biology directly underpins the trans-presentation mechanism described below.

Primary producers of IL-15 include dendritic cells (DCs), monocytes, macrophages, epithelial cells, skeletal muscle, and fibroblasts. Unlike IL-2, which is produced rapidly and transiently by activated T cells, IL-15 expression is constitutive in many non-lymphoid tissues, providing a continuous homeostatic signal to patrolling NK and memory T cells.

---

The IL-15 Receptor System: A Three-Chain Complex With Unique Architecture

The IL-15 receptor system consists of three chains, two of which are shared with the IL-2 receptor:

IL-15Rα: The Ultra-High-Affinity Presenter

IL-15Rα is a type I transmembrane glycoprotein characterized by a sushi domain (complement control protein module) at the N-terminus that constitutes the minimal binding unit for IL-15. This sushi domain confers an extraordinary affinity for IL-15 — approximately 1,000-fold higher than the affinity of IL-2Rα for IL-2 (Kd ~1 pM vs. ~100 pM). IL-15Rα is expressed on DCs, macrophages, stromal cells, and many non-hematopoietic cell types that produce IL-15, where it captures IL-15 intracellularly and escorts it to the surface.

The Trans-Presentation Paradigm

Unlike IL-2, which signals primarily in cis (the producing T cell also expresses high-affinity IL-2Rα/IL-2Rβ/γc), IL-15 signals predominantly in trans: the IL-15/IL-15Rα complex on one cell stimulates an adjacent cell expressing only IL-2Rβ/γc ([Dubois S et al., Immunity 2002,]()).

The sequence of events:

1. A DC or macrophage synthesizes IL-15 and IL-15Rα concurrently.

2. IL-15 binds IL-15Rα in the ER with picomolar affinity and is stabilized against degradation.

3. The IL-15/IL-15Rα complex is trafficked to the cell surface via the secretory pathway.

4. The surface-displayed complex engages IL-2Rβ/γc on an adjacent NK cell or CD8⁺ T cell.

5. This three-cell contact drives NK and memory T cell survival and proliferation.

Trans-presentation creates a critically distinct biology from classical cytokine signaling: it demands direct cell-cell contact, concentrates signaling at immune synapses, and limits IL-15 bioavailability to local tissue microenvironments. This architecture likely evolved to restrict NK cell and memory T cell proliferation to environments where antigen-presenting cells (APCs) are actively surveying for infection or tissue damage.

Research has also documented reverse signaling through IL-15Rα — when membrane-bound IL-15/IL-15Rα on the presenting cell is engaged by NK cell IL-2Rβ/γc, intracellular signals propagate into the presenting DC or macrophage itself, potentially regulating APC activation state ([Mortier E et al., J Exp Med 2008]()).

---

Intracellular Signaling: JAK-STAT5, PI3K-AKT, and MAPK Cascades

When IL-2Rβ and γc are engaged by the trans-presented IL-15 complex, the following intracellular cascades are activated:

JAK1/JAK3 → STAT5 Axis

• •JAK1 is constitutively associated with IL-2Rβ (CD122); JAK3 is associated with γc (CD132).
• •IL-15 binding promotes trans-phosphorylation of JAK1 and JAK3, activating their kinase domains.
• •Activated JAKs phosphorylate STAT5a and STAT5b on Tyr694/Tyr699, inducing homodimerization and nuclear translocation.
• •STAT5 target genes include Bcl-2, Bcl-xL, MCL-1 (survival genes), Pim-1/2 kinases, cyclin D1/D3 (cell cycle entry), and perforin and granzyme B in NK cells.

PI3K-AKT-mTOR Axis

• •IL-2Rβ cytoplasmic domain recruits phosphoinositide 3-kinase (PI3K) via adaptor proteins.
• •PI3K generates PIP₃, activating AKT and its downstream target mTORC1.
• •mTORC1 is essential for the metabolic reprogramming of NK cells in response to IL-15, upregulating glycolysis, oxidative phosphorylation capacity, and protein synthesis required for effector function.
• •This PI3K/AKT branch is relatively more prominent in NK cells compared with T cells, reflecting NK cells' constitutive IL-15 dependence for metabolic fitness.

MAPK/ERK Cascade

• •SHP-2 phosphatase and Grb2/SOS adapter complexes couple IL-2Rβ engagement to RAS → RAF → MEK → ERK activation.
• •ERK drives immediate-early gene transcription (c-Fos, c-Jun) and supports proliferative responses.

The integration of these three pathways determines whether a cell responds to IL-15 by surviving (STAT5/Bcl-2 dominant), proliferating (MAPK/cyclin D dominant), or acquiring effector function (mTOR/metabolic reprogramming dominant) — context determined by signal strength, duration, and costimulatory input.

---

IL-15 in NK Cell Development and Homeostasis

The single most critical biological role of IL-15 is the development, maintenance, and homeostatic proliferation of NK cells (Fehniger TA & Caligiuri MA, Blood 2001, PMID 11133739).

NK Cell Development

In both humans and mice, IL-15 signaling through IL-2Rβ/γc is required at the committed NK cell progenitor (NKP) stage in the bone marrow. Mice with targeted deletion of Il15, Il2rb, Il2rg, or Jak3 all display dramatic NK cell deficiency, confirming that this signaling axis is non-redundant.

Key developmental stages where IL-15 is required:

1. NKP → immature NK (iNK) transition: IL-15 drives commitment, upregulating Eomes and T-bet transcription factors.

2. iNK → mature NK (mNK): IL-15 sustains Bcl-2 and drives acquisition of effector molecules (perforin, granzymes, NKG2D, Ly49/KIR receptors).

3. Peripheral NK homeostasis: In the periphery, IL-15 trans-presentation by DCs and macrophages maintains NK cell numbers through homeostatic proliferation without overt activation.

NK Cell Activation vs. Homeostasis

An important research distinction: homeostatic IL-15 signaling (steady-state levels) maintains NK cell viability and baseline cytotoxic capacity, while acute/high-level IL-15 (as occurs during infection or with experimental recombinant IL-15 administration) drives robust NK cell proliferation and enhanced effector function. This dose-dependent distinction is essential for interpreting in vitro IL-15 stimulation experiments, where concentrations often exceed physiological homeostatic levels by orders of magnitude.

---

IL-15 and CD8⁺ Memory T Cell Homeostasis

The second canonical function of IL-15 is maintenance of antigen-experienced (memory) CD8⁺ T cells in the periphery. After resolution of an acute infection and contraction of the effector CD8⁺ T cell pool, the surviving memory cells depend on periodic tonic signals to persist long-term. These signals come from two cytokines: IL-7 (primarily maintaining quiescent central memory T cells, TCM, via STAT5/Bcl-2) and IL-15 (driving slow homeostatic proliferation of both TCM and effector memory T cells, TEM).

Key research findings:

• •IL-15-deficient mice accumulate markedly reduced numbers of CD8⁺ memory T cells after immunization, while naïve T cell numbers are minimally affected (Schluns KS et al., Nat Immunol 2000).
• •IL-15-driven memory T cell proliferation is MHC class I-independent — unlike antigen-driven proliferation, homeostatic proliferation by IL-15 does not require TCR engagement, allowing persistence without ongoing antigen encounter.
• •In lymphopenic hosts, IL-15 can drive lymphopenia-induced proliferation (LIP) of CD8⁺ T cells, a process relevant to post-transplant immune reconstitution research.

The functional distinction between IL-7 and IL-15 for memory CD8⁺ T cells is an active area of investigation: IL-7 predominantly maintains the long-lived quiescent pool, while IL-15 renews and activates this pool periodically, maintaining functional effector capacity in surveillance memory cells.

---

IL-15 in NKT Cells, γδ T Cells, and Intraepithelial Lymphocytes

Beyond NK and conventional CD8⁺ T cells, IL-15 plays specialized roles in:

NKT Cells (Natural Killer T Cells)

IL-15 is required for the homeostasis and activation of CD1d-restricted NKT cells. These cells express high levels of IL-2Rβ/γc and respond to IL-15 with IFN-γ production, linking innate-like T cell activation to NK cell effector functions.

γδ T Cells

Certain Vδ1⁺ γδ T cell subsets in the intestinal epithelium depend on IL-15 signaling for maintenance. Intestinal IL-15 production is upregulated in celiac disease, contributing to γδ T cell expansion and intraepithelial lymphocyte (IEL) activation that drives villous atrophy.

Intraepithelial Lymphocytes (IELs)

IELs in the intestinal epithelium are a major IL-15-dependent population. IL-15 produced by enterocytes in response to stress, infection, or gluten peptides (in celiac disease) maintains IEL survival and cytotoxic activity. This makes IL-15 a key research target in intestinal immunopathology.

---

IL-15 in Autoimmunity and Inflammatory Disease Research

Given its potent effects on innate immune cells and memory T cells, IL-15 dysregulation is implicated in multiple inflammatory conditions:

Rheumatoid Arthritis (RA)

IL-15 is abundantly expressed in synovial fluid macrophages and fibroblasts from RA patients. Research has shown that synovial IL-15 drives TNF-α production by T cells through direct cell-cell contact (trans-presentation), amplifying local inflammation. Anti-IL-15 antibody research (e.g., AMG 714) has been investigated in RA and other inflammatory conditions.

Celiac Disease

Celiac disease represents one of the clearest examples of pathological IL-15 biology. Gluten-derived peptides activate innate immune pathways in intestinal epithelial cells, driving IL-15 overexpression. Excess IL-15 then:

1. Activates NK-like IELs to kill enterocytes expressing the stress molecule MICA/MICB (via NKG2D).

2. Promotes HLA-DQ2/8-restricted CD4⁺ T cell activation through enhanced APC function.

3. Drives the intestinal γδ T cell expansion characteristic of the disease.

Research with anti-IL-15 approaches in celiac disease has demonstrated that blocking IL-15 can reduce IEL cytotoxicity in ex vivo intestinal biopsy models.

Type 1 Diabetes and Other Autoimmune Conditions

IL-15 elevations have been documented in Type 1 diabetes islets, multiple sclerosis lesions, and psoriatic skin, suggesting a common role in tissue-specific autoimmune inflammation mediated by NK and memory T cell reactivation.

---

IL-15 in Cancer Immunology Research

IL-15's role in maintaining NK cells and memory CD8⁺ T cells — two key anti-tumor effector populations — has made it a major focus of cancer immunotherapy research.

Endogenous IL-15 and Anti-Tumor Surveillance

Research in IL-15-deficient mice demonstrates impaired rejection of transplantable tumors and increased susceptibility to carcinogen-induced tumors, confirming the importance of endogenous IL-15 for homeostatic anti-tumor surveillance. In the tumor microenvironment (TME), IL-15 produced by DCs and activated macrophages can sustain NK and CD8⁺ T cell function against local immunosuppressive signals.

IL-15 and NK Cell Memory-Like Properties

Research by Fehniger and colleagues ([Cooper MA et al., J Exp Med 2009]()) established that NK cells briefly activated by IL-12 + IL-18 + IL-15 acquire memory-like NK cell properties: upon rechallenge weeks later, these cells display enhanced IFN-γ production, demonstrating that innate NK cells can acquire functional memory analogous (but not identical) to adaptive T cell memory. This phenomenon has significant implications for cancer immunotherapy research and adoptive NK cell transfer strategies.

Tumor-Induced IL-15 Resistance

Tumors can subvert IL-15 signaling through:

• •Downregulation of NK cell receptor NKG2D by shedding MICA/MICB decoys.
• •Upregulation of TGF-β and IL-10 that oppose IL-15-driven STAT5 activation.
• •Expression of PD-L1 that co-inhibits NK cell activation independent of IL-15.

Research with combined IL-15 + checkpoint inhibitor approaches aims to overcome these evasion mechanisms.

---

Recombinant IL-15 and Research Tools

Recombinant Human IL-15 (rhIL-15)

Recombinant human IL-15 (114 aa, E. coli-derived or mammalian-produced) is the standard research reagent for in vitro NK cell and memory T cell stimulation, expansion, and functional assays. Key points for researchers:

• •E. coli-derived rhIL-15 lacks glycosylation; activity is comparable to native protein for most signaling assays.
• •Optimal in vitro concentration: 10–100 ng/mL for NK cell expansion (significantly above physiological homeostatic levels).
• •Half-life: Circulating IL-15 is rapidly cleared (t₁/₂ <1 hour in vivo due to receptor-mediated uptake), requiring frequent dosing or sustained-delivery formulations for in vivo research.

IL-15 Superagonist Complexes

A key advance in IL-15 research tools is the development of IL-15 superagonist (SA) complexes, which combine IL-15 (or IL-15 mutants) with soluble IL-15Rα sushi domain to pre-form the trans-presenting complex. This dramatically enhances activity:

• •RLI (Recombinant Linker IL-15): Fusion protein connecting IL-15 via a linker to the IL-15Rα sushi domain; ~50-fold more potent than monomeric IL-15 in stimulating NK and memory CD8⁺ T cells.
• •N-803 (Nogapendekin alfa inbakicept; originally ALT-803): IL-15 superagonist consisting of the IL-15N72D mutant (enhanced IL-2Rβ binding) fused to IL-15Rα sushi domain-Fc fusion. N-803 forms a dimeric complex with ~25-fold greater biological activity than rhIL-15. N-803 has been used extensively as a research tool to study NK and T cell expansion in vivo and has been approved by the FDA (2024) in combination with BCG for BCG-unresponsive non-muscle-invasive bladder cancer — the mechanism involving trans-presentation to urothelial NK and T cells represents a direct clinical application of the trans-presentation biology. For laboratory research, N-803/ALT-803 is widely available as a reagent for ex vivo NK cell activation and expansion protocols.
• •IL-15-based chimeric antigen receptor (CAR-NK/CAR-T) systems: Research approaches have embedded membrane-anchored IL-15 or IL-15/IL-15Rα fusions into CAR-NK and CAR-T constructs to provide autocrine IL-15 signaling, sustaining persistence without exogenous cytokine supplementation.

IL-15Rα Sushi Domain Fusion Partners

The IL-15Rα sushi domain (residues 1–66 of the mature protein) is widely used as a research tool:

• •Fused to Fc domains to create half-life-extended IL-15SA complexes.
• •Used in surface plasmon resonance (SPR) studies to characterize IL-15 binding kinetics.
• •Applied in co-culture systems to generate trans-presented IL-15 signals in cell-free formats.

---

Key Research Applications and Experimental Considerations

NK Cell Expansion for Adoptive Transfer Research

IL-15 (often combined with IL-2 or IL-12) drives robust ex vivo NK cell expansion protocols used in adoptive NK cell transfer research. Key protocol consideration: IL-15 alone maintains NK cell viability and moderate expansion, while IL-15 + IL-12 priming generates memory-like NK cells with enhanced IFN-γ secretion capacity upon tumor rechallenge.

Memory CD8⁺ T Cell Generation and Maintenance

For generating and maintaining antigen-specific memory CD8⁺ T cell populations in vitro, IL-15 (10–50 ng/mL) combined with IL-7 in minimal stimulation media supports long-term maintenance without antigen-driven expansion, preserving a resting memory phenotype.

Distinguishing IL-15 vs. IL-2 Effects

Since IL-15 and IL-2 share IL-2Rβ/γc, distinguishing their effects requires specific neutralizing antibodies or recombinant cytokines combined with IL-15Rα/IL-2Rα blocking:

• •Anti-IL-15 antibodies (e.g., AMG 714 research grade): specifically neutralize IL-15 trans-presentation.
• •Anti-IL-2Rα (daclizumab analog): blocks IL-2 signaling without affecting IL-15.
• •IL-15-specific reporter cell lines expressing only IL-2Rβ/γc (lacking IL-2Rα) provide clean IL-15-selective readouts.

Autoimmunity Research Models

• •Anti-IL-15 treatment in collagen-induced arthritis (CIA) mouse models reduces joint inflammation.
• •IL-15 transgenic mice (overexpressing IL-15) develop NK and CD8⁺ T cell lymphoproliferative disease and serve as models of IL-15-driven pathology.
• •Intestinal organoid co-culture systems with IL-15-stimulated IELs model celiac disease epithelial damage ex vivo.

---

Comparison Table: IL-15 vs. IL-2

---

Summary

IL-15 is a master regulator of innate and adaptive immune memory, operating through a uniquely sophisticated trans-presentation mechanism that physically couples cytokine delivery to direct cell-cell contact between DCs/macrophages and NK or memory CD8⁺ T cells. Its complete dependence on IL-15Rα for in vivo activity — creating a picomolar-affinity surface complex — distinguishes it mechanistically from all other cytokines and makes the sushi domain of IL-15Rα the foundation for engineered superagonist research tools including RLI and N-803. From intestinal homeostasis and anti-viral surveillance to autoimmune pathology and cancer immunotherapy research, IL-15 biology continues to yield fundamental insights into how the immune system maintains long-lived cellular protection.

References

• •PMID: 42712421
• •PMID: 42705066
• •PMID: 42694134

Research Use Only. All applications described herein are for laboratory and research investigation. IL-15 and IL-15-based reagents are not approved for diagnostic or clinical use outside of specific regulatory contexts, and all experimental protocols must comply with institutional and regulatory guidelines for research use only (RUO) materials.